Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Comparison of the effects of insulin monotherapy and combination therapy with ipragliflozin and insulin on glucose toxicity in type 2 diabetes mellitus : a randomized controlled trial

Next Previous
Trial Profile

Comparison of the effects of insulin monotherapy and combination therapy with ipragliflozin and insulin on glucose toxicity in type 2 diabetes mellitus : a randomized controlled trial

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Aug 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ipragliflozin (Primary) ; Insulin
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use

Most Recent Events

  • 30 Jul 2018 Status changed from recruiting to completed.
  • 10 Apr 2017 Planned End Date changed from 31 Mar 2017 to 31 Mar 2018.
  • 04 Nov 2015 Status changed from not yet recruiting to recruiting, as reported by University Hospital Medical Information Network - Japan record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top